Clinical Trial Update: A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors [Phase 1]

View source ↗

Summary

This document announces a Phase I trial evaluating RGT-419B in patients with HR-positive, HER2-negative advanced breast cancer and other solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• RGT-419B

Snippet

Sponsor: Regor Pharmaceuticals Inc. | Conditions: Breast Cancer, Advanced Solid Tumor | Phase 1 | Status: ACTIVE_NOT_RECRUITING